Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder classified as an α-synucleinopathy, characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The disease involves selective and severe neuronal loss across multiple neural systems, leading to the dysregulation of autonomic functions, movement control, and motor coordination.
MSA demonstrates widespread neuronal loss across several key brain regions:
The hallmark of MSA is the formation of glial cytoplasmic inclusions (GCIs) in oligodendrocytes, but neuronal involvement includes:
The pathogenesis of MSA involves multiple interconnected mechanisms:
α-Synuclein Aggregation: Pathological phosphorylation and truncation of alpha-synuclein leads to toxic oligomer formation and fibril aggregation. [5]
Oligodendroglial Dysfunction: Primary oligodendrocyte pathology contributes to secondary neuronal damage through demyelination and trophic support failure. [6]
Mitochondrial Dysfunction: Complex I deficiency and oxidative stress accelerate neuronal death. [7]
Neuroinflammation: Activated microglia and astrocytosis contribute to progressive neuronal loss. [8]
MSA neurons face significant white matter abnormalities:
Current research focuses on identifying reliable biomarkers:
Emerging treatments target:
α-Synuclein aggregation inhibitors
Neuroprotective agents
Remyelination strategies
Autonomic function modulators [12]
Multiple System Atrophy (Disease Page
Alpha-Synuclein Alpha-Synucleinopathies
Dopaminergic Neurons (SNPC)
Oligodendrocytes in MSA
Multiple System Atrophy Pathway
MSA Treatment
MSA Biomarkers
Tredici et al. Nigrostriatal involvement in MSA (2021). 2021. ↩︎
Kon et al. Olivopontocerebellar atrophy in MSA (2020). 2020. ↩︎
Nishie et al. Neuronal α-synucleinopathy in MSA (2003). 2003. ↩︎
Wenning et al. Oligodendroglial pathology in MSA (2022). 2022. ↩︎
Stamelou et al. Mitochondrial dysfunction in MSA (2019). 2019. ↩︎
Valente et al. Neuroinflammation in MSA (2021). 2021. ↩︎
Krismer et al. MSA-P vs MSA-C phenotype (2023). 2023. ↩︎
Kim et al. Clinical subtypes of MSA (2020). 2020. ↩︎
Poewe et al. Biomarkers for atypical parkinsonism (2022). 2022. ↩︎
Meissner et al. Disease-modifying therapies in MSA (2023). 2023. ↩︎